Spots Global Cancer Trial Database for onvansertib
Every month we try and update this database with for onvansertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia | NCT05549661 | Recurrent Chron... Refractory Chro... | Biospecimen Col... Bone Marrow Asp... Onvansertib Ultrasound Imag... | 18 Years - | Mayo Clinic | |
| Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | NCT03303339 | Acute Myeloid L... | Onvansertib Cytarabine Decitabine | 18 Years - | Cardiff Oncology | |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | NCT04446793 | Metastatic Colo... KRAS Gene Mutat... | Onvansertib Bevacizumab FOLFIRI | 18 Years - | Cardiff Oncology | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | NCT06398587 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Onvansertib Gemcitabine Nab-paclitaxel Electrocardiogr... Magnetic Resona... Positron Emissi... Biospecimen Col... Biospecimen Col... Computed Tomogr... | 18 Years - | OHSU Knight Cancer Institute | |
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04752696 | Pancreatic Duct... | Onvansertib Nanoliposomal i... Leucovorin Fluorouracil | 18 Years - | Cardiff Oncology | |
| Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | NCT03303339 | Acute Myeloid L... | Onvansertib Cytarabine Decitabine | 18 Years - | Cardiff Oncology | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | NCT05450965 | Small-cell Lung... Small Cell Lung... | Onvansertib | 18 Years - | University of Maryland, Baltimore | |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | NCT04446793 | Metastatic Colo... KRAS Gene Mutat... | Onvansertib Bevacizumab FOLFIRI | 18 Years - | Cardiff Oncology | |
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04752696 | Pancreatic Duct... | Onvansertib Nanoliposomal i... Leucovorin Fluorouracil | 18 Years - | Cardiff Oncology | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer | NCT04005690 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Cobimetinib Olaparib Onvansertib Azenosertib | 18 Years - | OHSU Knight Cancer Institute | |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | NCT06398587 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Onvansertib Gemcitabine Nab-paclitaxel Electrocardiogr... Magnetic Resona... Positron Emissi... Biospecimen Col... Biospecimen Col... Computed Tomogr... | 18 Years - | OHSU Knight Cancer Institute | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer | NCT04005690 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Cobimetinib Olaparib Onvansertib Azenosertib | 18 Years - | OHSU Knight Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
